NVCR NovoCure Ltd

Price (delayed)

$120.74

Market cap

$12.51B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.04

Enterprise value

$12.73B

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating ...

Highlights

The company's quick ratio has surged by 62% YoY

The equity has increased by 48% year-on-year and by 7% since the previous quarter

The net income has plunged by 139% from the previous quarter and by 139% YoY

NVCR's EPS has dropped by 133% since the previous quarter and by 131% year-on-year

Sector: Healthcare

Industry: Medical Instruments & Supplies

Website: http://www.novocure.com

Peers: NVAX ONVO ORTX

Key stats

What are the main financial stats of NVCR

Market

Shares outstanding

103.65M

Market cap

$12.51B

Enterprise value

$12.73B

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

31.43

Price to sales (P/S)

22.93

EV/EBIT

863.92

EV/EBITDA

524.97

EV/Sales

23.36

Earnings

Revenue

$544.83M

EBIT

$14.73M

EBITDA

$24.24M

Free cash flow

$113.26M

Per share

EPS

-$0.04

Free cash flow per share

$1.09

Book value per share

$3.84

Revenue per share

$5.26

TBVPS

$10.6

Balance sheet

Total assets

$1.1B

Total liabilities

$699.79M

Debt

$572.51M

Equity

$397.27M

Working capital

$929.36M

Liquidity

Debt to equity

1.44

Current ratio

Quick ratio

8.77

Net debt/EBITDA

8.74

Margins

EBITDA margin

4.4%

Gross margin

79.5%

Net margin

-0.8%

Operating margin

2.7%

Efficiency

Return on assets

-0.5%

Return on equity

-1.2%

Return on invested capital

1.6%

Return on capital employed

1.5%

Return on sales

2.7%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

NVCR stock price

How has the NovoCure stock price performed over time

Intraday

-1.02%

1 week

7.59%

1 month

-7.92%

1 year

-3.44%

YTD

-30.22%

QTD

3.93%

Financial performance

How have NovoCure's revenue and profit performed over time

Revenue

$544.83M

Gross profit

$433.31M

Operating income

$14.73M

Net income

-$4.57M

Gross margin

79.5%

Net margin

-0.8%

The net income has plunged by 139% from the previous quarter and by 139% YoY

NovoCure's net margin has plunged by 136% from the previous quarter and by 128% YoY

NovoCure's operating income has surged by 102% YoY but it has shrunk by 56% QoQ

NovoCure's operating margin has shrunk by 58% QoQ but it has surged by 50% YoY

Growth

What is NovoCure's growth rate over time

Valuation

What is NovoCure stock price valuation

P/E

N/A

P/B

31.43

P/S

22.93

EV/EBIT

863.92

EV/EBITDA

524.97

EV/Sales

23.36

NVCR's EPS has dropped by 133% since the previous quarter and by 131% year-on-year

The equity has increased by 48% year-on-year and by 7% since the previous quarter

The price to book (P/B) is 25% lower than the last 4 quarters average of 41.9 but 11% higher than the 5-year quarterly average of 28.3

The company's revenue rose by 33% YoY and by 3.3% QoQ

NVCR's price to sales (P/S) is 29% lower than its last 4 quarters average of 32.1 but 25% higher than its 5-year quarterly average of 18.4

Efficiency

How efficient is NovoCure business performance

NovoCure's return on equity has shrunk by 136% QoQ and by 124% YoY

The company's return on assets has shrunk by 133% QoQ and by 121% YoY

NovoCure's ROIC has plunged by 66% from the previous quarter and by 16% YoY

NVCR's return on sales has dropped by 58% since the previous quarter but it has surged by 50% year-on-year

Dividends

What is NVCR's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for NVCR.

Financial health

How did NovoCure financials performed over time

NovoCure's total assets is 57% more than its total liabilities

NovoCure's total liabilities has surged by 168% YoY

NovoCure's total assets has soared by 107% YoY and by 2.8% from the previous quarter

NovoCure's debt is 44% more than its equity

NVCR's debt to equity has soared by 136% YoY but it is down by 6% QoQ

The equity has increased by 48% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.